Free Trial
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel
NASDAQ:EQ

Equillium Q3 2026 Earnings Date & Estimates

Equillium logo
$1.30 -0.02 (-1.52%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$1.32 +0.01 (+1.15%)
As of 10/14/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Equillium is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. The conference call is scheduled for November 11, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Equillium in Q3 2026

Equillium is expected to post earnings of -$0.05 per share. In the same quarter a year earlier Equillium reported -$0.06 per share. Equillium last reported on August 13, 2026, posting -$0.04 per share and beating the -$0.0540 consensus estimate. Equillium has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.05
Prior-Year EPS
-$0.06

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.04 (Beat by +$0.0140)
EPS Beat Rate
6 of last 8 quarters

Prepare for the Q3 2026 Call

Equillium Q3 2026 Earnings FAQ

Equillium (NASDAQ:EQ) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Equillium's Q3 2026 earnings conference call is scheduled for Wednesday, November 11, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Equillium to post earnings of -$0.05 per share for Q3 2026.

Equillium Earnings Headlines

Equillium, Inc. Receives Australian Regulatory Clearance to Initiate First-In-Human Clinical Trial of Eq504
October 7, 2026  |  marketscreener.comM
Equillium Gains Australian Nod For Phase 1 Study Of EQ504; Dosing In Nov'26
October 7, 2026  |  rttnews.comhttps://www.rttnews.com/3697152/equillium-gains-australian-nod-for-phase-1-study-of-eq504-dosing-in-nov-26.aspx
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.tc pixel
 |  Investors Alley (Ad)
Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference
October 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/06/3375998/0/en/equillium-announces-poster-presentation-at-the-50th-anniversary-la-jolla-immunology-conference.html
Equillium (NASDAQ: EQ) clears Australia for EQ504 dosing
October 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31090060
Equillium Gets Australian Clearance for Phase 1 Trial of Ulcerative Colitis Drug Candidate EQ504
October 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/equillium-gets-australian-clearance-phase-210626016.html
See More Equillium Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Equillium? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Equillium and other key companies, straight to your email.

About Equillium

Equillium (NASDAQ:EQ) is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory diseases. The company’s approach centers on modulating immune pathways involved in disease progression, with the goal of addressing conditions that have limited treatment options.

Equillium’s lead product candidate is itolizumab, a monoclonal antibody that targets CD6, an immune-cell receptor involved in the regulation of T-cell activity. The company is evaluating itolizumab in immune-mediated conditions, including acute graft-versus-host disease and lupus nephritis. Equillium also has an earlier-stage pipeline that includes peptide-based therapies designed to inhibit inflammatory pathways such as interleukin-17.

Founded in 2017 and headquartered in San Diego, California, Equillium has built its development programs through internal research and strategic collaborations, including an agreement with Biocon for rights related to itolizumab. As a clinical-stage company, Equillium’s activities are primarily focused on research, clinical development and advancing its pipeline toward potential regulatory approval.

View Equillium Profile
Earnings Tools